AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Summit Therapeutics PLC (NASDAQ:SMMT)
15.07 USD
+0.210 1.413%Sponsored Reports
Loading...
| Previous Close (in USD) | 14.86 |
|---|---|
| Change | +0.210 1.413% |
| 52 W H/L (in USD) | 5.390/1.520 |
| EBITDA (in USD) | -114.75M |
| PE Ratio | 6.87 |
| Volume | 4361903 |
| Diluted Eps TTM | 0.38 |
| Total Assets (in USD) | 202.949M |
|---|---|
| Total Liabilities (in USD) | 125.257M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 71.425M |
| Market Cap (in USD) | 1,832.168 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.705M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Employees: 105
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Robert W. Duggan | CEO & Exec. Chairman | 1944 |
| 2. | Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA | Co-CEO, Pres & Director | 1970 |
| 3. | Dr. Urte Gayko Ph.D. | Head of Regulatory Affairs, Quality Assurance & Safety and Director | 1971 |
| 4. | Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
| 5. | Mr. Ankur Dhingra | Chief Financial Officer | 1976 |
| 6. | Ms. Michelle Avery | Director of Investor Relations | NA |
| 7. | Dr. Elaine Carla Stracker J.D., Ph.D. | Head of Compliance? & Gen. Counsel | 1961 |
| 8. | Mr. Campbell Hair | Head of HR? | NA |
| 9. | Dr. Anne Heatherington | Head of Clinical Devel. and Quantitative Sciences | NA |
| 10. | Ms. Divya Chari | Head of Global Clinical Operations | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 | 31-01-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -78.782M | -88.602M | -52.91M | 4.994M | 6.598M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -74.381M | -86.147M | -52.697M | 4.994M | 9.872M |
| Selling General Administrative | 26.7M | 23.611M | 19.232M | - | 16.187M |
| Gross Profit | 0.704M | 1.809M | 0.86M | 43.012M | 56.388M |
| Reconciled Depreciation | 2.514M | 2.455M | 2.003M | - | 1.493M |
| Ebit | -72.089M | -88.641M | -53.193M | -25.556M | 12.381M |
| Ebitda | -60.803M | -86.186M | -51.475M | 15.156M | 13.874M |
| Depreciation And Amortization | 11.286M | 2.455M | 1.718M | 0.524M | 1.493M |
| Operating Income | -72.089M | -86.186M | -53.193M | 15.156M | 12.381M |
| Other Operating Expenses | 64.283M | 87.995M | 53.194M | -39.182M | 47.688M |
| Interest Expense | 4.401M | 0.281M | 0.255M | 0M | 0.556M |
| Tax Provision | - | 0M | -0.213M | - | -3.274M |
| Interest Income | - | 0M | 0.004M | - | 0.005M |
| Net Interest Income | -4.401M | -0.281M | -0.251M | - | 3.101M |
| Income Tax Expense | -4.401M | -2.455M | -0.213M | -3.844M | -3.274M |
| Total Revenue | 0.704M | 1.809M | 0.86M | 43.012M | 56.413M |
| Total Operating Expenses | 64.283M | 87.995M | 53.194M | -39.182M | 47.688M |
| Cost Of Revenue | - | - | - | - | 0.025M |
| Total Other Income Expense Net | -6.693M | -2.416M | 0.283M | -10.162M | -5.783M |
| Net Income From Continuing Ops | -78.782M | -88.602M | -52.697M | - | 9.872M |
| Net Income Applicable To Common Shares | -78.782M | -88.602M | -52.697M | -24.035M | 7.527M |
Balance Sheet
(Currency in USD)| Breakdown | 31-01-2024 | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 |
|---|---|---|---|---|---|
| Total Assets | 202.949M | 664.168M | 113.374M | 102.498M | 24.439M |
| Intangible Assets | - | - | 10.399M | 11.515M | 10.604M |
| Other Current Assets | 0.181M | 0.486M | 1.201M | 1.523M | 5.8M |
| Total Liab | 125.257M | 537.514M | 30.09M | 23.045M | -18.098M |
| Total Stockholder Equity | 77.692M | 126.654M | 83.284M | 79.453M | 42.537M |
| Other Current Liab | 0.717M | 16.967M | 12.219M | 4.99M | 1.494M |
| Common Stock | 7.017M | 2.11M | 0.98M | 0.826M | 3.359M |
| Capital Stock | 7.017M | 2.11M | 0.98M | 0.826M | - |
| Retained Earnings | -993.258M | -378.33M | -299.548M | -214.74M | -97.619M |
| Good Will | 1.893M | 1.798M | 2.009M | 2.03M | 1.814M |
| Other Assets | - | 0.577M | 25.521M | - | -16.377M |
| Cash | 71.425M | 348.607M | 71.791M | 66.417M | 26.858M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 20.405M | 38.782M | 25.623M | 19.89M | -1.836M |
| Current Deferred Revenue | 14.212M | - | 7.939M | 8.37M | -0.831M |
| Net Debt | 34.674M | 170.156M | -69.009M | -65.952M | -27.863M |
| Short Term Debt | 2.809M | 21.46M | 1.091M | 0.39M | -1.005M |
| Short Long Term Debt | - | 19.77M | - | - | - |
| Short Long Term Debt Total | 106.099M | 518.763M | 2.782M | 0.465M | -1.005M |
| Other Stockholder Equity | 1066.381M | 504.767M | 384.049M | 293.367M | 42.537M |
| Property Plant Equipment | - | 5.081M | 3.484M | 1.279M | 1.167M |
| Total Current Assets | 189.712M | 656.712M | 97.312M | 66.417M | 26.858M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 114.817M | - | - | - | - |
| Net Receivables | 0.848M | 6.115M | 17.159M | 10.187M | 5.13M |
| Long Term Debt | 100M | 494.54M | - | - | - |
| Inventory | 2.441M | 301.504M | 7.161M | -11.71M | - |
| Accounts Payable | 2.667M | 0.355M | 4.374M | 6.14M | 3.389M |
| Accumulated Other Comprehensive Income | -2.448M | -1.893M | -2.197M | -3.794M | - |
| Non Currrent Assets Other | 5.281M | 0.577M | 0.17M | 21.257M | - |
| Non Current Assets Total | 13.237M | 7.456M | 16.062M | 36.081M | 13.958M |
| Capital Lease Obligations | 6.099M | 4.453M | 2.782M | 0.465M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-01-2023 | 31-01-2022 | 31-01-2021 | 31-01-2020 | 31-01-2019 |
|---|---|---|---|---|---|
| Investments | -0.624M | -0.306M | -0.421M | - | -0.411M |
| Total Cashflows From Investing Activities | -0.624M | -0.306M | -0.421M | -0.287M | -0.313M |
| Total Cash From Financing Activities | 620.244M | 77.916M | 50.551M | 33.113M | 43.855M |
| Net Income | -78.782M | -88.602M | -52.697M | -25.556M | 6.598M |
| Change In Cash | 576.816M | 5.374M | 2.575M | 6.756M | 8.861M |
| Begin Period Cash Flow | 71.791M | 66.417M | 63.842M | 20.102M | 26.365M |
| End Period Cash Flow | 648.607M | 71.791M | 66.417M | 26.858M | 35.226M |
| Total Cash From Operating Activities | -41.582M | -72.587M | -48.111M | -26.663M | -35.143M |
| Depreciation | 2.514M | 2.455M | 2.003M | 1.473M | 1.493M |
| Other Cashflows From Investing Activities | - | - | -0.421M | 0.004M | 0.004M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | 3.595M | -6.607M | - | 0M |
| Sale Purchase Of Stock | - | - | - | - | 0M |
| Other Cashflows From Financing Activities | 545.244M | 112.916M | 0.551M | 33.113M | -1.588M |
| Capital Expenditures | 0.624M | 0.306M | 0.421M | 0.119M | 0.164M |
| Change In Working Capital | 8.616M | -0.067M | 0.619M | 4.375M | -51.181M |
| Other Non Cash Items | 14.122M | 0.497M | -0.385M | -28.136M | 1.726M |
| Free Cash Flow | -42.206M | -72.893M | -48.532M | -26.782M | -35.307M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 2 years ago | 5048900 |
| 2. | Fidelity Select Biotechnology | 2 years ago | 4354329 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 3591598 |
| 4. | iShares Russell 2000 ETF | 2 years ago | 2690215 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1882444 |
| 6. | Fidelity Small Cap Index | 2 years ago | 1185193 |
| 7. | Fidelity Select Health Care | 2 years ago | 1000000 |
| 8. | iShares Russell 2000 Growth ETF | 2 years ago | 975789 |
| 9. | Fidelity Extended Market Index | 2 years ago | 719642 |
| 10. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 713485 |
| 11. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 691500 |
| 12. | iShares Biotechnology ETF | 2 years ago | 605784 |
| 13. | Fidelity Advisor Health Care I | 2 years ago | 600000 |
| 14. | Schwab US Small-Cap ETF™ | 2 years ago | 595901 |
| 15. | Fidelity Growth Company Fund | 2 years ago | 526499 |
| 16. | Direxion Daily S&P Biotech Bull 3X ETF | 2 years ago | 508069 |
| 17. | ALPS Medical Breakthroughs ETF | 2 years ago | 491087 |
| 18. | Vanguard Health Care ETF | 2 years ago | 472726 |
| 19. | Vanguard Russell 2000 ETF | 2 years ago | 432710 |
| 20. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 422700 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 9759383 |
| 2. | Vanguard Group Inc | 2 years ago | 7269243 |
| 3. | Geode Capital Management, LLC | 2 years ago | 3085666 |
| 4. | State Street Corporation | 2 years ago | 2456168 |
| 5. | Northern Trust Corp | 2 years ago | 1108089 |
| 6. | Charles Schwab Investment Management Inc | 2 years ago | 1016545 |
| 7. | Morgan Stanley - Brokerage Accounts | 2 years ago | 704272 |
| 8. | Rafferty Asset Management, LLC | 2 years ago | 650286 |
| 9. | Steward Partners Investment Advisory, LLC | 2 years ago | 600000 |
| 10. | Nuveen Asset Management, LLC | 2 years ago | 565624 |
| 11. | Citigroup Inc | 2 years ago | 559006 |
| 12. | Federated Hermes Inc | 2 years ago | 551769 |
| 13. | ALPS Advisors Inc | 2 years ago | 494924 |
| 14. | Goldman Sachs Group Inc | 2 years ago | 388816 |
| 15. | Bank of New York Mellon Corp | 2 years ago | 342529 |
| 16. | Barclays PLC | 2 years ago | 318565 |
| 17. | Sectoral Asset Management Inc | 2 years ago | 315000 |
| 18. | JPMorgan Chase & Co | 2 years ago | 296205 |
| 19. | Swiss National Bank | 2 years ago | 275000 |
| 20. | Susquehanna International Group, LLP | 2 years ago | 230350 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...